Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$30.63M |
$4.75
+1.71%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$30.28M |
$2.10
+9.69%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$29.91M |
$0.86
+3.31%
|
|
KTCC
Key Tronic Corporation
Vietnam medical device manufacturing capability highlighted, aligning with Medical Devices & Biometrics.
|
$29.30M |
$2.70
+3.05%
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$29.00M |
$0.32
+1.64%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$28.97M |
$1.08
-1.82%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$28.58M |
$8.65
-3.65%
|
|
ELUT
Elutia Inc.
Elutia's EluPro is a cardiology device used with cardiac implanted electronic devices (CIEDs), directly tying to Cardiology Devices.
|
$28.53M |
$0.68
+9.26%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$28.43M |
$0.68
+1.26%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$28.36M |
$1.75
-0.29%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$28.03M |
$1.48
+1.72%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$27.79M |
$7.11
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$27.54M |
$2.30
+17.95%
|
|
LESL
Leslie's, Inc.
AccuBlue water-testing systems and related diagnostic testing capabilities are direct testing instruments offered to customers.
|
$27.54M |
$3.03
+1.00%
|
|
DRIO
DarioHealth Corp.
Integrated Medical Devices & Biometrics (smart glucose meters and biofeedback sensors) are part of the offering.
|
$27.23M |
$12.09
+1.34%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$26.88M |
$1.31
-0.38%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$26.87M |
$0.65
-0.32%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$26.83M |
$0.47
+2.85%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$26.44M |
$3.84
+1.86%
|
|
NRXS
NeurAxis, Inc.
Core product line: Neuromodulation devices (IB-Stim PENFS).
|
$26.32M |
$2.71
+2.08%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$25.88M |
$0.04
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$25.54M |
$2.13
-4.69%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$25.39M |
$0.99
+11.85%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$25.13M |
$2.08
+2.46%
|
|
CDIX
Cardiff Lexington Corporation
Nova Ortho & Spine provides diagnostic and related assessment services, aligning with Diagnostics & Lab Services in Healthcare.
|
$24.94M |
$1.30
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$24.85M |
$1.11
+0.45%
|
|
RVP
Retractable Technologies, Inc.
Core product category directly manufactured and sold: passive-safety syringes designed to prevent needlestick injuries.
|
$24.61M |
$0.85
+2.91%
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$24.58M |
$2.08
+3.48%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$24.40M |
$1.85
+4.52%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$24.39M |
$3.83
+0.26%
|
|
MLSS
Milestone Scientific Inc.
Direct dental equipment manufacturing (DPS-based systems and related dental devices) as the dental segment is a core business.
|
$23.80M |
$0.31
+0.06%
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$23.59M |
$1.21
+2.99%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$22.79M |
$7.73
+15.20%
|
|
AKTX
Akari Therapeutics, Plc
Company pivot to oncology biotech focusing on next-generation ADC platforms.
|
$22.08M |
$0.46
+3.45%
|
Showing page 31 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
